Warning letters, 483s, Recalls, Import Alerts, Audit observations
The FDA inspected Colgate-Palmolive/Tom’s of Maine, Inc’s Sanford facility in the US in May 2024.
The USFDA issued a warning letter in January 2025 to Sanofi’s API facility in Framingham,
Indoco Remedies’ Goa Plant (FEI 3005124189) received a warning letter from the FDA following critical
The USFDA has issued a Warning Letter to Hyderabad-based OTC manufacturer Akron Formulations for critical
Aurobindo arm Eugia Pharma site at Sangareddy, Telengana was inspected by USFDA in Jan -Feb
Sun Pharma initiated recall of several drugs manufactured at Dadra site (India) for cGMP deviation
FDA had issued USFDA 483 in December 2022 to Novartis US site at Morris Plains,
USFDA issued a Warning letter to Intas, Matoda, Ahmedabad facility (FEI 3003157498) on 21 November
Bayer is recalling one lot of Vitrakvi® (larotrectinib) Oral Solution 20 mg/mL in 100mL glass
Natco Pharma (india) Kothur facility was inspected by USFDA in October 2023. The site (FEI
